PS-341; LDP-341; NSC 681239 MedChemExpress (MCE)

Product Name	Bortezomib
Synonyms	dpba MLM341 VELCADE Bortezomib BortezoMib R BortezoMib-D8 MG-341 PS-341 Synonyms dpba MLM341 VELCADE Bortezomib BortezoMib R BortezoMib-D8 MG-341 PS-341 BortezoMib Base bortezoMib(other) VELCADE(BORTEZOMIB) Bortezomib for research N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide [(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
CAS	179324-69-7
EINECS	605-854-3
Chemical Formula	C19H25BN4O4
Molecular Weight	384.24
inchi	InChI=1/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
Package	10 mM * 1 mL;5 mg;10 mg;50 mg;100 mg;200 mg
Price	Email to quote
Descriptions	Bortezomib Bortezomib MedChemExpress (MCE) HY-10227 179324-69-7 PS-341 Descriptions Bortezomib Bortezomib MedChemExpress (MCE) HY-10227 179324-69-7 PS-341 LDP-341 NSC 681239 99.91% 4°C, protect from light In solvent : -80°C, 6 months -20°C, 1 month (protect from light) Room temperature in continental US may vary elsewhere. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity. Bortezomib (PS-341) (100 nM 8 hours) results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1[1]. Bortezomib (PS-341) (5-100 nM 20 hours) induces apoptosis in mantle-cell lymphoma (MCL) cell lines[3]. Bortezomib (PS-341) (20 nM 1-14 hours) induces Noxa up-regulation in both MCL cell lines[3]. The IC50 of Bortezomib (PS-341) is found to be 2.46 nM for 26S proteasome in the B16F10 cells[4]. Bortezomib (PS-341) suppresses several anti-apoptotic proteins (e.g., Bcl-XL, Bcl-2, and STAT-3)[5]. Bortezomib (PS-341) (0.3-1 mg/kg i.v. once weekly for 4 weeks) inhibits PC-3 Tumor Growth in Nude Mice[1]. Ki: 0.6 nM (20S proteasome)[1] Cellular Effect Cell Line Type Value Description References \| \| \| \| \| \| \| \| \| \| [1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1 59(11):2615-22. [Content Brief]* [2]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011 1(7):913-24. [Content Brief] [3]. Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1 107(1):257-64. [Content Brief] [4]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr 3(2):333-9. [Content Brief] [5]. Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec 12(67):471-80. [Content Brief] [6]. Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13 281(2):1107-18. [Content Brief]
Supplier Website	http://www.medchemexpress.com/Bortezomib.html
Last Update	2025-10-14 16:03:33

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-10-14 16:03:33

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-10-14 16:03:33

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-10-14 16:03:33

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-10-14 16:03:33

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-10-14 16:03:33

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-10-14 16:03:33

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-10-14 16:03:33

Thalidomide-PEG4-NH2

Category: Signaling Pathways
CAS: 2387510-82-7
Last Update: 2025-10-14 16:03:33


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	http://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact